Uterine cancer survivors are at higher risk of developing cardiovascular problems after 10 years of treatment. Endometrial or uterine cancer is the fourth most commonly diagnosed cancer among women in the US.
‘Monitoring for cardiovascular diseases is essential in uterine cancer survivors after 10 years of cancer diagnosis.’
Incidence rates among women under the age of 50 have been increasing by 1.3% per year since 1988 and by 1.9% among women over the age of 50 since 2005. It was the 6th most common cause of death from cancer among women in the United States in 2017, with an estimated 10,920 deaths. As of 2017, there were an estimated 757,200 endometrial cancer survivors in the United States.
Previous studies of long-term health effects among endometrial cancer survivors have focused largely on quality of life, mental health, obesity, and adverse sexual side effects. But the high overall survival rate among people diagnosed with the cancer, the projected increase in the number of such cancer diagnoses, the introduction of more complex therapies, and the high mortality due to cardiovascular disease among endometrial cancer survivors, suggest that other long-term health effects are important to assess.
Novel Approach for Treating Uterine Cancer
A new treatment for endometrial cancer developed loads a drug into the tumor-targeting nanoparticles making the tumor cells vulnerable to chemotherapy's toxicity.
A new treatment for endometrial cancer developed loads a drug into the tumor-targeting nanoparticles making the tumor cells vulnerable to chemotherapy's toxicity.
The results of the study indicate that approximately 25.7% of cancer survivors were diagnosed with heart diseases five to ten years after cancer diagnosis. Endometrial cancer survivors were 47% more likely to be diagnosed with a disease of the heart between one of five years after cancer diagnosis and 33% more likely to be diagnosed with a disease of the heart between five to ten years after the initial cancer diagnosis.
Advertisement
New Prognosis Marker for Uterine Cancer Identified
Inhibition of a newly identified protein P-S6S240 is effective in the therapy and prognosis of patients with leiomyosarcoma, a form of uterine cancer.
Inhibition of a newly identified protein P-S6S240 is effective in the therapy and prognosis of patients with leiomyosarcoma, a form of uterine cancer.
Researchers found associations for hypotension, diseases of veins and lymphatics, and other diseases of veins and lymphatics.
Advertisement
Rare Uterine Cancer Can Be Treated With a Breast Cancer Drug
Phase 2 trial of Trastuzumab with chemotherapy regimen has shown positive results with respect to rare uterine cancer, finds a new study. The Trastuzumab drug is currently used to treat certain breast cancers.
Phase 2 trial of Trastuzumab with chemotherapy regimen has shown positive results with respect to rare uterine cancer, finds a new study. The Trastuzumab drug is currently used to treat certain breast cancers.
Some elevated risk persisted for cardiovascular diseases at five to ten years. Compared to patients who had surgery, patients who additionally had radiation therapy and/or chemotherapy were at increased risk for heart and circulatory system disorders between one to five years after cancer diagnosis.
Prior studies have reported similar proportions of endometrial cancer survivors who have hypertension diagnoses, but this study is the first to quantify risk for hypertension after cancer diagnosis among uterine cancer survivors compared to the general population.
This study suggests that increased monitoring for cardiovascular diseases may be important for endometrial cancer patients for 10 years after cancer diagnosis.
Source-Eurekalert
